Pharmacokinetics of cefuroxime after intravenous, intramuscular, and subcutaneous administration to dogs
Cefuroxime pharmacokinetic profile was investigated in 6 Beagle dogs after single intravenous, intramuscular, and subcutaneous administration at a dosage of 20 mg/kg. Blood samples were withdrawn at predetermined times over a 12‐h period. Cefuroxime plasma concentrations were determined by HPLC. Dat...
Gespeichert in:
| Veröffentlicht in: | Journal of veterinary pharmacology and therapeutics 2016-02, Vol.39 (1), p.40-44 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 44 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | Journal of veterinary pharmacology and therapeutics |
| container_volume | 39 |
| creator | Albarellos, G. A. Montoya, L. Lorenzini, P. M. Passini, S. M. Lupi, M. P. Landoni, M. F. |
| description | Cefuroxime pharmacokinetic profile was investigated in 6 Beagle dogs after single intravenous, intramuscular, and subcutaneous administration at a dosage of 20 mg/kg. Blood samples were withdrawn at predetermined times over a 12‐h period. Cefuroxime plasma concentrations were determined by HPLC. Data were analyzed by compartmental analysis. Peak plasma concentration (Cₘₐₓ), time‐to‐peak plasma concentration (Tₘₐₓ), and bioavailability for the intramuscular and subcutaneous administration were (mean ± SD) 22.99 ± 7.87 μg/mL, 0.43 ± 0.20 h, and 79.70 ± 14.43% and 15.37 ± 3.07 μg/mL, 0.99 ± 0.10 h, and 77.22 ± 21.41%, respectively. Elimination half‐lives and mean residence time for the intravenous, intramuscular, and subcutaneous administration were 1.12 ± 0.19 h and 1.49 ± 0.21 h; 1.13 ± 0.13 and 1.79 ± 0.24 h; and 1.04 ± 0.23 h and 2.21 ± 0.23 h, respectively. Significant differences were found between routes for Kₐ, MAT, Cₘₐₓ, Tₘₐₓ, t½₍ₐ₎, and MRT. T > MIC = 50%, considering a MIC of 1 μg/mL, was 11 h for intravenous and intramuscular administration and 12 h for the subcutaneous route. When a MIC of 4 μg/mL is considered, T > MIC = 50% for intramuscular and subcutaneous administration was estimated in 8 h. |
| doi_str_mv | 10.1111/jvp.12239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760865622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760865622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4579-605513a8fb5d7ff47d72e74cbec99770a2e2847080357050983490d67a219d5f3</originalsourceid><addsrcrecordid>eNp1kU1PFTEUhhsjkevVhX9Au9SEgdN2-jFLvVGEEMQoYtw0vZ0WCjPTazuD8O-pDrCzSdOc5HnfnDxF6BWBXVLO3uX1ZpdQyponaEGY4BVVij9FCyA1VFIqto2e53wJAEwR8gxtU94oyilboIuTC5N6Y-NVGNwYbMbRY-v8lOJN6B02fnQJh2FM5toNcco789BP2U6dSTvYDC3O09pOoxlcAbBp-zCEXKAxxAGPEbfxPL9AW9502b28f5fo9NPH76vP1dGX_YPV-6PK1lw2lQDOCTPKr3krva9lK6mTtV072zRSgqGOqlqCAsYlcGgUqxtohTSUNC33bInezr2bFH9PLo-6D9m6rpu300QKUIKLomuJ3s2oTTHn5LzepNCbdKsJ6L9idRGr_4kt7Ov72mndu_aRfDBZgL0Z-BM6d_v_Jn344-ShspoTxZW7eUyYdKWFZJLrs-N9_Uv8PP7KVmf6Q-HfzLw3UZvzFLI-_UaBCCiXl69md-erm8M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760865622</pqid></control><display><type>article</type><title>Pharmacokinetics of cefuroxime after intravenous, intramuscular, and subcutaneous administration to dogs</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Albarellos, G. A. ; Montoya, L. ; Lorenzini, P. M. ; Passini, S. M. ; Lupi, M. P. ; Landoni, M. F.</creator><creatorcontrib>Albarellos, G. A. ; Montoya, L. ; Lorenzini, P. M. ; Passini, S. M. ; Lupi, M. P. ; Landoni, M. F.</creatorcontrib><description>Cefuroxime pharmacokinetic profile was investigated in 6 Beagle dogs after single intravenous, intramuscular, and subcutaneous administration at a dosage of 20 mg/kg. Blood samples were withdrawn at predetermined times over a 12‐h period. Cefuroxime plasma concentrations were determined by HPLC. Data were analyzed by compartmental analysis. Peak plasma concentration (Cₘₐₓ), time‐to‐peak plasma concentration (Tₘₐₓ), and bioavailability for the intramuscular and subcutaneous administration were (mean ± SD) 22.99 ± 7.87 μg/mL, 0.43 ± 0.20 h, and 79.70 ± 14.43% and 15.37 ± 3.07 μg/mL, 0.99 ± 0.10 h, and 77.22 ± 21.41%, respectively. Elimination half‐lives and mean residence time for the intravenous, intramuscular, and subcutaneous administration were 1.12 ± 0.19 h and 1.49 ± 0.21 h; 1.13 ± 0.13 and 1.79 ± 0.24 h; and 1.04 ± 0.23 h and 2.21 ± 0.23 h, respectively. Significant differences were found between routes for Kₐ, MAT, Cₘₐₓ, Tₘₐₓ, t½₍ₐ₎, and MRT. T > MIC = 50%, considering a MIC of 1 μg/mL, was 11 h for intravenous and intramuscular administration and 12 h for the subcutaneous route. When a MIC of 4 μg/mL is considered, T > MIC = 50% for intramuscular and subcutaneous administration was estimated in 8 h.</description><identifier>ISSN: 0140-7783</identifier><identifier>EISSN: 1365-2885</identifier><identifier>DOI: 10.1111/jvp.12239</identifier><identifier>PMID: 25982523</identifier><language>eng</language><publisher>England: Blackwell Scientific Publications</publisher><subject>Animals ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - blood ; Anti-Bacterial Agents - pharmacokinetics ; Area Under Curve ; Biological Availability ; Cefuroxime - administration & dosage ; Cefuroxime - blood ; Cefuroxime - pharmacokinetics ; Cross-Over Studies ; Dogs - blood ; Drug Administration Routes ; Female ; Half-Life ; Male</subject><ispartof>Journal of veterinary pharmacology and therapeutics, 2016-02, Vol.39 (1), p.40-44</ispartof><rights>2015 John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4579-605513a8fb5d7ff47d72e74cbec99770a2e2847080357050983490d67a219d5f3</citedby><cites>FETCH-LOGICAL-c4579-605513a8fb5d7ff47d72e74cbec99770a2e2847080357050983490d67a219d5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvp.12239$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvp.12239$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25982523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Albarellos, G. A.</creatorcontrib><creatorcontrib>Montoya, L.</creatorcontrib><creatorcontrib>Lorenzini, P. M.</creatorcontrib><creatorcontrib>Passini, S. M.</creatorcontrib><creatorcontrib>Lupi, M. P.</creatorcontrib><creatorcontrib>Landoni, M. F.</creatorcontrib><title>Pharmacokinetics of cefuroxime after intravenous, intramuscular, and subcutaneous administration to dogs</title><title>Journal of veterinary pharmacology and therapeutics</title><addtitle>J. vet. Pharmacol. Therap</addtitle><description>Cefuroxime pharmacokinetic profile was investigated in 6 Beagle dogs after single intravenous, intramuscular, and subcutaneous administration at a dosage of 20 mg/kg. Blood samples were withdrawn at predetermined times over a 12‐h period. Cefuroxime plasma concentrations were determined by HPLC. Data were analyzed by compartmental analysis. Peak plasma concentration (Cₘₐₓ), time‐to‐peak plasma concentration (Tₘₐₓ), and bioavailability for the intramuscular and subcutaneous administration were (mean ± SD) 22.99 ± 7.87 μg/mL, 0.43 ± 0.20 h, and 79.70 ± 14.43% and 15.37 ± 3.07 μg/mL, 0.99 ± 0.10 h, and 77.22 ± 21.41%, respectively. Elimination half‐lives and mean residence time for the intravenous, intramuscular, and subcutaneous administration were 1.12 ± 0.19 h and 1.49 ± 0.21 h; 1.13 ± 0.13 and 1.79 ± 0.24 h; and 1.04 ± 0.23 h and 2.21 ± 0.23 h, respectively. Significant differences were found between routes for Kₐ, MAT, Cₘₐₓ, Tₘₐₓ, t½₍ₐ₎, and MRT. T > MIC = 50%, considering a MIC of 1 μg/mL, was 11 h for intravenous and intramuscular administration and 12 h for the subcutaneous route. When a MIC of 4 μg/mL is considered, T > MIC = 50% for intramuscular and subcutaneous administration was estimated in 8 h.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - blood</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Area Under Curve</subject><subject>Biological Availability</subject><subject>Cefuroxime - administration & dosage</subject><subject>Cefuroxime - blood</subject><subject>Cefuroxime - pharmacokinetics</subject><subject>Cross-Over Studies</subject><subject>Dogs - blood</subject><subject>Drug Administration Routes</subject><subject>Female</subject><subject>Half-Life</subject><subject>Male</subject><issn>0140-7783</issn><issn>1365-2885</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1PFTEUhhsjkevVhX9Au9SEgdN2-jFLvVGEEMQoYtw0vZ0WCjPTazuD8O-pDrCzSdOc5HnfnDxF6BWBXVLO3uX1ZpdQyponaEGY4BVVij9FCyA1VFIqto2e53wJAEwR8gxtU94oyilboIuTC5N6Y-NVGNwYbMbRY-v8lOJN6B02fnQJh2FM5toNcco789BP2U6dSTvYDC3O09pOoxlcAbBp-zCEXKAxxAGPEbfxPL9AW9502b28f5fo9NPH76vP1dGX_YPV-6PK1lw2lQDOCTPKr3krva9lK6mTtV072zRSgqGOqlqCAsYlcGgUqxtohTSUNC33bInezr2bFH9PLo-6D9m6rpu300QKUIKLomuJ3s2oTTHn5LzepNCbdKsJ6L9idRGr_4kt7Ov72mndu_aRfDBZgL0Z-BM6d_v_Jn344-ShspoTxZW7eUyYdKWFZJLrs-N9_Uv8PP7KVmf6Q-HfzLw3UZvzFLI-_UaBCCiXl69md-erm8M</recordid><startdate>201602</startdate><enddate>201602</enddate><creator>Albarellos, G. A.</creator><creator>Montoya, L.</creator><creator>Lorenzini, P. M.</creator><creator>Passini, S. M.</creator><creator>Lupi, M. P.</creator><creator>Landoni, M. F.</creator><general>Blackwell Scientific Publications</general><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201602</creationdate><title>Pharmacokinetics of cefuroxime after intravenous, intramuscular, and subcutaneous administration to dogs</title><author>Albarellos, G. A. ; Montoya, L. ; Lorenzini, P. M. ; Passini, S. M. ; Lupi, M. P. ; Landoni, M. F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4579-605513a8fb5d7ff47d72e74cbec99770a2e2847080357050983490d67a219d5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - blood</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Area Under Curve</topic><topic>Biological Availability</topic><topic>Cefuroxime - administration & dosage</topic><topic>Cefuroxime - blood</topic><topic>Cefuroxime - pharmacokinetics</topic><topic>Cross-Over Studies</topic><topic>Dogs - blood</topic><topic>Drug Administration Routes</topic><topic>Female</topic><topic>Half-Life</topic><topic>Male</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Albarellos, G. A.</creatorcontrib><creatorcontrib>Montoya, L.</creatorcontrib><creatorcontrib>Lorenzini, P. M.</creatorcontrib><creatorcontrib>Passini, S. M.</creatorcontrib><creatorcontrib>Lupi, M. P.</creatorcontrib><creatorcontrib>Landoni, M. F.</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Albarellos, G. A.</au><au>Montoya, L.</au><au>Lorenzini, P. M.</au><au>Passini, S. M.</au><au>Lupi, M. P.</au><au>Landoni, M. F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of cefuroxime after intravenous, intramuscular, and subcutaneous administration to dogs</atitle><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle><addtitle>J. vet. Pharmacol. Therap</addtitle><date>2016-02</date><risdate>2016</risdate><volume>39</volume><issue>1</issue><spage>40</spage><epage>44</epage><pages>40-44</pages><issn>0140-7783</issn><eissn>1365-2885</eissn><abstract>Cefuroxime pharmacokinetic profile was investigated in 6 Beagle dogs after single intravenous, intramuscular, and subcutaneous administration at a dosage of 20 mg/kg. Blood samples were withdrawn at predetermined times over a 12‐h period. Cefuroxime plasma concentrations were determined by HPLC. Data were analyzed by compartmental analysis. Peak plasma concentration (Cₘₐₓ), time‐to‐peak plasma concentration (Tₘₐₓ), and bioavailability for the intramuscular and subcutaneous administration were (mean ± SD) 22.99 ± 7.87 μg/mL, 0.43 ± 0.20 h, and 79.70 ± 14.43% and 15.37 ± 3.07 μg/mL, 0.99 ± 0.10 h, and 77.22 ± 21.41%, respectively. Elimination half‐lives and mean residence time for the intravenous, intramuscular, and subcutaneous administration were 1.12 ± 0.19 h and 1.49 ± 0.21 h; 1.13 ± 0.13 and 1.79 ± 0.24 h; and 1.04 ± 0.23 h and 2.21 ± 0.23 h, respectively. Significant differences were found between routes for Kₐ, MAT, Cₘₐₓ, Tₘₐₓ, t½₍ₐ₎, and MRT. T > MIC = 50%, considering a MIC of 1 μg/mL, was 11 h for intravenous and intramuscular administration and 12 h for the subcutaneous route. When a MIC of 4 μg/mL is considered, T > MIC = 50% for intramuscular and subcutaneous administration was estimated in 8 h.</abstract><cop>England</cop><pub>Blackwell Scientific Publications</pub><pmid>25982523</pmid><doi>10.1111/jvp.12239</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-7783 |
| ispartof | Journal of veterinary pharmacology and therapeutics, 2016-02, Vol.39 (1), p.40-44 |
| issn | 0140-7783 1365-2885 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760865622 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - blood Anti-Bacterial Agents - pharmacokinetics Area Under Curve Biological Availability Cefuroxime - administration & dosage Cefuroxime - blood Cefuroxime - pharmacokinetics Cross-Over Studies Dogs - blood Drug Administration Routes Female Half-Life Male |
| title | Pharmacokinetics of cefuroxime after intravenous, intramuscular, and subcutaneous administration to dogs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A21%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20cefuroxime%20after%20intravenous,%20intramuscular,%20and%20subcutaneous%20administration%20to%20dogs&rft.jtitle=Journal%20of%20veterinary%20pharmacology%20and%20therapeutics&rft.au=Albarellos,%20G.%20A.&rft.date=2016-02&rft.volume=39&rft.issue=1&rft.spage=40&rft.epage=44&rft.pages=40-44&rft.issn=0140-7783&rft.eissn=1365-2885&rft_id=info:doi/10.1111/jvp.12239&rft_dat=%3Cproquest_cross%3E1760865622%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760865622&rft_id=info:pmid/25982523&rfr_iscdi=true |